Versant Capital Management
NPCE icon

Versant Capital Management’s Neuropace NPCE Stock Holding History

Versant Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-48
Closed -$763 – 2847
2026
Q2 		$763 Buy
+48
New +$772 ﹤0.01% 2672

Other funds holding NPCE

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management's NPCE Position: Q3 2026 in Review

Versant Capital Management sold out of Neuropace (NPCE) in Q3 2026, closing a stake of 48 shares — an estimated $763 sold.

Versant Capital Management first reported a position in NPCE in Q2 2026 and held it in 1 quarter. The position peaked at $763 in Q2 2026. 5 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Versant Capital Management reported no remaining Neuropace position as of Q3 2026 after selling out during the quarter.
  • Versant Capital Management sold 48 Neuropace shares in Q3 2026, an estimated $763.
  • Versant Capital Management first reported a position in Neuropace in Q2 2026 and held it in 1 quarter.
  • Versant Capital Management's Neuropace position peaked at $763 in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.